450nm semiconductor blue laser vaporization prostatectomy in the treatment of high-risk benign prostatic hyperplasia patients without discontinuing anticoagulant drugs
10.12483/j.issn.1009-8291.2026.02.005
- VernacularTitle:450nm半导体蓝激光前列腺汽化切除术治疗不停用抗凝药高危良性前列腺增生患者初探
- Author:
Yongdi WU
1
;
Jiaqing SUN
1
;
Liang CHAO
1
;
Chen ZHOU
1
;
Dong QIU
1
;
Pengfei SHI
1
Author Information
1. Department of Urology, The Third Affiliated Hospital of Xuzhou Medical University, Xuzhou 221003, China
- Publication Type:Journal Article
- Keywords:
benign prostatic hyperplasia;
450nm semiconductor blue laser;
anticoagulant drugs;
vaporization prostatectomy
- From:
Journal of Modern Urology
2026;31(2):131-134
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of 450nm semiconductor blue laser vaporization prostatectomy in high-risk benign prostatic hyperplasia (BPH) patients without discontinuing anticoagulant drugs, so as to provide a safe and effectiveminimally invasive treatment option for such patients. Methods A total of 40 high-risk BPH patients who underwent 450nm semiconductor blue laser vaporization prostatectomy in our hospital during Sep. 2023 and Dec. 2024 were selected as the research subjects. The patients were divided into two groups: the oral medication group took oral anticoagulants during the perioperative period, while the discontinuation group discontinued anticoagulants, with 20 cases in either group. The perioperative indicators and changes including international prostate symptom score (IPSS), quality of life score (QoL), maximum urinary flow rate (Qmax) and post-void residual (PVR) were compared between the two groups.Results There were no statistically significant differences between the oral medication group and discontinuation group in operation time [(28.83±15.52)min vs. (26.43±14.02)min], postoperative catheter indwelling time [(3.04±0.89) d vs. (3.23±1.01) d], bladder irrigation time [(27.36±7.54) h vs. (25.46±7.10) h], and decrease in hemoglobin [(8.08±1.82)g/L vs. (7.56±1.68)g/L] (all P＞0.05). Three month after surgery, Qmax in both groups was higher, while IPSS, QoL and PVR were significantly lower (P＜0.05), but there were no statistically significant differences between the two groups (P＞0.05). No serious complications such as urinary incontinence or massive hemorrhage occurred.Conclusion 450nm semiconductor blue laser vaporization prostatectomy for high-risk BPH patients is characterized by high vaporization efficiency and good hemostatic effects. It can significantly improve the clinical symptoms with high safety, especially for high-risk patients who cannot discontinue anticoagulants.
